6 recruiting. 6 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Recruiting 6 |
| Phase 2 | 4 | Recruiting 4 |
Follow SCLC: new trials by email Literature Review of SCLC trials Research Report on SCLC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC HLX3901 - SCLC, NEC | Phase 1 | Recruiting | Shanghai Henlius Biotech | 138 | 2026-04-17 | 2026-07-08 |
| 68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer Sequential [18F]-FDG PET/CT, [68Ga]Ga-PFD3 PET/CT scan - SCLC, SCLC, Extensive Stage | Phase 1 / Phase 2 | Recruiting | Peking University First Hospital | 30 | 2025-10-22 | 2026-06-18 |
| First in Human Study of TUB-030 in Patients With Advanced Solid Tumors TUB-030 - Advanced Solid Tumors, HNSCC | Phase 1 / Phase 2 | Recruiting | Gilead Sciences | 250 | 2024-12-13 | 2026-09-11 |
| A Study of ZL-1310 in Subjects With Small Cell Lung Cancer ZL-1310, Atezolizumab, Carboplatin - SCLC | Phase 1 | Recruiting | Zai Lab (Shanghai) Co., Ltd. | 339 | 2024-01-23 | 2026-10-16 |
| A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors JAB-8263 - NSCLC, SCLC | Phase 1 / Phase 2 | Recruiting | Jacobio Pharmaceuticals Co., Ltd. | 152 | 2021-05-07 | 2026-01-09 |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) rezatapopt, pembrolizumab - Advanced Solid Tumor, Advanced Malignant Neoplasm | Phase 1 / Phase 2 | Recruiting | PMV Pharmaceuticals, Inc | 300 | 2020-10-29 | 2026-10-02 |
Head and Neck Neoplasms (2) · Ovarian Neoplasms (2) · Small Cell Lung Carcinoma (2) · Triple Negative Breast Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Disease (1) · Endometrial Neoplasms (1) · Gallbladder Neoplasms (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Prostatic Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
Neoplasms by Site (4) · Neoplasms (3) · Adnexal Diseases (2) · Breast Diseases (2) · Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Genital Diseases (2) · Genital Diseases, Female (2) · Genital Neoplasms, Female (2) · Gonadal Disorders (2) · Lung Diseases (2)
Carboplatin (1) · atezolizumab (1) · pembrolizumab (1)
Gilead Sciences (1) · Jacobio Pharmaceuticals Co., Ltd. (1) · PMV Pharmaceuticals, Inc (1) · Peking University First Hospital (1) · Shanghai Henlius Biotech (1) · Zai Lab (Shanghai) Co., Ltd. (1)
China (4) · Spain (3) · United States (3) · France (2) · Australia (1) · Canada (1) · Germany (1) · Israel (1) · Italy (1) · Romania (1) · Singapore (1) · South Korea (1) · United Kingdom (1)
Marc Fellous, MD (1) · Yariv Houvras, MD, PhD (1)